PE20220143A1 - Agonistas de glp-1r y usos de los mismos - Google Patents
Agonistas de glp-1r y usos de los mismosInfo
- Publication number
- PE20220143A1 PE20220143A1 PE2021001694A PE2021001694A PE20220143A1 PE 20220143 A1 PE20220143 A1 PE 20220143A1 PE 2021001694 A PE2021001694 A PE 2021001694A PE 2021001694 A PE2021001694 A PE 2021001694A PE 20220143 A1 PE20220143 A1 PE 20220143A1
- Authority
- PE
- Peru
- Prior art keywords
- membered
- saturated
- ring
- compounds
- alkoxy
- Prior art date
Links
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 title abstract 3
- 239000000556 agonist Substances 0.000 title abstract 2
- 102100032882 Glucagon-like peptide 1 receptor Human genes 0.000 title 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 8
- 150000001875 compounds Chemical class 0.000 abstract 5
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- BGCPLWWYPZAURQ-UHFFFAOYSA-N 5-[[5-chloro-2-(2,2,6,6-tetramethylmorpholin-4-yl)pyrimidin-4-yl]amino]-3-(3-hydroxy-3-methylbutyl)-1-methylbenzimidazol-2-one Chemical group ClC=1C(=NC(=NC=1)N1CC(OC(C1)(C)C)(C)C)NC1=CC2=C(N(C(N2CCC(C)(C)O)=O)C)C=C1 BGCPLWWYPZAURQ-UHFFFAOYSA-N 0.000 abstract 2
- 125000000041 C6-C10 aryl group Chemical group 0.000 abstract 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 abstract 2
- 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 229910052805 deuterium Inorganic materials 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 150000002431 hydrogen Chemical group 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 2
- 101150063022 CHRD gene Proteins 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 101100274355 Danio rerio chd gene Proteins 0.000 abstract 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000001280 Prediabetic State Diseases 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 201000009104 prediabetes syndrome Diseases 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente descripcion proporciona compuestos de Formula (I) o una sal farmaceuticamente aceptable del mismo, en donde: el enlace en el anillo C indica un enlace simple o un enlace doble; X1, X2, X3, X4 y X5 se seleccionan cada uno independientemente de N y CH; W se selecciona de O, S, CR5R6 y NR5'; el anillo B es heteroarilo de 6 miembros, heterociclilo monociclico de 6 miembros o fenilo, en donde Y1 se selecciona de N, NH, CH y CH2; el anillo C es ciclohexilo, fenilo o piridilo; L es CHRd, O, S o NR5'; el anillo D es heteroarilo biciclico; EE es -COOH o un sustituto del grupo carboxilico; cada Ra y Rb se seleccionan independientemente de hidrogeno, deuterio, halogeno, -CN, alquilo C1-C6, alcoxi C1-C6, NR5'R6', arilo de 6-10 miembros, heteroarilo de 5-8 miembros, cicloalquilo de 3-8 miembros saturado o parcialmente saturado y heterociclilo de 3-8 miembros saturado o parcialmente saturado, en donde el alquilo C1-C6 o alcoxi C1-C6; cada Rc y Rd se seleccionan independientemente de hidrogeno, deuterio, halogeno, -CN, alquilo C1-C6, alcoxi C1-C6, NR5'R6', arilo de 6-10 miembros, heteroarilo de 5-8 miembros, cicloalquilo de 3-8 miembros saturado o parcialmente saturado y heterociclilo de 3-8 miembros saturado o parcialmente saturado; cada R1, R2, R3 y R4 se selecciona o sustituye segun la invencion. Son compuestos preferidos los seleccionados de los compuestos 74-102 y 246-334 o unal sal, estereoisomero, solvato o hidrato farmaceuticamente aceptable del mismo. Tambien se refiere a una composicion farmaceutica y metodos que comprenden el compuesto de la invencion. Dichos compuestos son agonistas del receptor de GLP-1 (GLP-1R) utiles en el tratamiento de diabetes mellitus tipo 2 (T2DM), prediabetes, obesidad, enfermedad del higado graso no alcoholico, esteatohepatitis no alcoholica y enfermedad cardiovascular.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019082381 | 2019-04-12 | ||
| PCT/CN2020/084203 WO2020207474A1 (en) | 2019-04-12 | 2020-04-10 | Glp-1r agonists and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20220143A1 true PE20220143A1 (es) | 2022-01-27 |
Family
ID=72750961
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2021001694A PE20220143A1 (es) | 2019-04-12 | 2020-04-10 | Agonistas de glp-1r y usos de los mismos |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US20230278991A1 (es) |
| EP (1) | EP3953344A4 (es) |
| JP (2) | JP7635145B2 (es) |
| CN (1) | CN113853371B (es) |
| AU (1) | AU2020256647B2 (es) |
| BR (1) | BR112021020335A2 (es) |
| CA (1) | CA3136375A1 (es) |
| CL (1) | CL2021002649A1 (es) |
| CO (1) | CO2021015060A2 (es) |
| CR (1) | CR20210562A (es) |
| CU (1) | CU20210083A7 (es) |
| DO (1) | DOP2021000208A (es) |
| EA (1) | EA202192684A1 (es) |
| IL (1) | IL287128A (es) |
| MA (1) | MA55627A (es) |
| MX (1) | MX2021012492A (es) |
| PE (1) | PE20220143A1 (es) |
| PH (1) | PH12021552557A1 (es) |
| SA (1) | SA521430550B1 (es) |
| SG (1) | SG11202110825WA (es) |
| WO (1) | WO2020207474A1 (es) |
Families Citing this family (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA130273C2 (uk) | 2018-11-22 | 2026-01-07 | Цилу Реґор Терапьютикс Інк. | Агоністи glp-1r та їх застосування |
| US10954221B2 (en) | 2019-04-12 | 2021-03-23 | Qilu Regor Therapeutics Inc. | GLP-1R agonists and uses thereof |
| TWI751585B (zh) | 2019-06-28 | 2022-01-01 | 美商美國禮來大藥廠 | 類升糖素肽1受體促效劑 |
| PE20221040A1 (es) * | 2019-10-25 | 2022-06-17 | Gilead Sciences Inc | Compuestos moduladores de glp-1r |
| CN114761395B (zh) * | 2019-12-02 | 2024-11-15 | 现代药品株式会社 | Glp-1受体激动剂 |
| CA3168543A1 (en) | 2020-01-29 | 2021-08-05 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| MA58498B1 (fr) | 2020-02-07 | 2024-08-30 | Gasherbrum Bio, Inc. | Agonistes hétérocycliques de glp-1 |
| WO2021160127A1 (en) * | 2020-02-13 | 2021-08-19 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| JOP20220213A1 (ar) * | 2020-03-18 | 2023-01-30 | Lg Chemical Ltd | ناهضة مستقبل الببتيد-1 الشبيه بالغلوكاغون (glp-1)، وتركيبة صيدلانية تشتمل عليه، وطريقة تحضيره |
| KR102563111B1 (ko) * | 2020-03-18 | 2023-08-04 | 주식회사 엘지화학 | Glp-1 수용체 효능제, 이를 포함하는 약학적 조성물 및 이의 제조방법 |
| TW202144340A (zh) * | 2020-04-03 | 2021-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用 |
| CN113831337B (zh) * | 2020-06-24 | 2023-03-24 | 广州市恒诺康医药科技有限公司 | Glp-1受体激动剂及其药物组合物和用途 |
| IL300155A (en) | 2020-08-06 | 2023-03-01 | Gasherbrum Bio Inc | Heterocyclic glp-1 agonists |
| CN116406360A (zh) | 2020-08-28 | 2023-07-07 | 加舒布鲁姆生物公司 | 杂环glp-1激动剂 |
| CN115515956B (zh) * | 2020-09-29 | 2024-06-25 | 深圳信立泰药业股份有限公司 | 一种苯并咪唑类衍生物及其制备方法和医药用途 |
| EP4227299A4 (en) | 2020-10-12 | 2025-04-09 | Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. | GLP-1 RECEPTOR AGONIST, BENZIMIDAZOLONE AND ITS USE |
| US20230391760A1 (en) * | 2020-10-13 | 2023-12-07 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| JP7769695B2 (ja) * | 2020-10-14 | 2025-11-13 | キル・レガー・セラピューティクス・インコーポレーテッド | Ｇｌｐ－１ｒアゴニストの結晶形態およびその使用 |
| CN114478497B (zh) * | 2020-11-12 | 2023-10-20 | 杭州中美华东制药有限公司 | 芳基烷基酸类glp-1受体激动剂及其用途 |
| WO2022109182A1 (en) * | 2020-11-20 | 2022-05-27 | Gilead Sciences, Inc. | Polyheterocyclic glp-1 r modulating compounds |
| EP4242202A4 (en) * | 2020-11-27 | 2024-05-15 | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Benzimidazole derivative and preparation method therefor and medical use thereof |
| KR20230124956A (ko) * | 2020-12-25 | 2023-08-28 | 스촨 하이스코 파마수티컬 씨오., 엘티디 | 5원 고리 유도체 및 이의 의학적 용도 |
| CN114805336A (zh) * | 2021-01-20 | 2022-07-29 | 江苏恒瑞医药股份有限公司 | 稠合咪唑类化合物、其制备方法及其在医药上的应用 |
| AU2022212019A1 (en) * | 2021-01-28 | 2023-08-03 | Carmot Therapeutics, Inc. | Gpcr receptor agonists, pharmaceutical compositions comprising the same, and methods for their use |
| WO2022184849A1 (en) | 2021-03-04 | 2022-09-09 | Les Laboratoires Servier | Glp-1r agonists, uses and pharmaceutical compositions thereof |
| US12091404B2 (en) | 2021-03-11 | 2024-09-17 | Gilead Sciences, Inc. | GLP-1R modulating compounds |
| US12180197B2 (en) | 2021-03-11 | 2024-12-31 | Gilead Sciences, Inc. | GLP-1R modulating compounds |
| EP4317142A4 (en) * | 2021-03-22 | 2025-02-26 | Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. | THIOPHENE-TYPE GLP-1 RECEPTOR AGONIST AND ITS USE |
| EP4317145A4 (en) | 2021-03-24 | 2025-03-12 | Shionogi & Co., Ltd | Pharmaceutical composition containing glp-1 receptor agonist having fused ring |
| US20220348564A1 (en) * | 2021-03-24 | 2022-11-03 | Eccogene (Shanghai) Co., Ltd. | Phenyl-[1,3]dioxolo[4,5-c]pyridinyl-phenyl-, phenyl-[1,3]dioxolo[4,5-c]pyridinyl-heteroaryl-, or phenyl-(1,3)dioxo[4,5-c]pyridinyl-piperidinyl-methyl-oxetanylmethyl-1h-benzo[d]imidazole-carboxylic acid derivatives and methods of using same |
| JP2024514259A (ja) * | 2021-04-08 | 2024-03-29 | エルジー・ケム・リミテッド | Ｇｌｐ－１受容体作動薬、それを含む薬学的組成物、およびその製造方法 |
| EP4303215A4 (en) * | 2021-04-08 | 2024-09-18 | Lg Chem, Ltd. | GLP-1 RECEPTOR AGONIST, PHARMACEUTICAL COMPOSITION COMPRISING IT AND PREPARATION METHOD THEREOF |
| IL307590A (en) * | 2021-04-12 | 2023-12-01 | Novartis Ag | 2-((4-((S)-2-(4-CHLORO-2-FLUOROPHENYL)-2-METHYLBENZO[D][1,3]DIOXOL-4-YL)PIPERIDIN-1-YL)METHYL)-1 -(((S)-OXETAN-2-YL)MTHYL)-1H-IMIDAZOLE DERIVATIVES AS ACTIVATORS OF THE GLP1 RECEPTOR FOR THE TREATMENT OF OBESITY |
| BR112023021561A2 (pt) | 2021-04-21 | 2023-12-19 | Gilead Sciences Inc | Compostos de carbóxi-benzimidazol moduladores de glp-1r |
| JP7642098B2 (ja) * | 2021-04-21 | 2025-03-07 | ギリアード サイエンシーズ， インコーポレイテッド | カルボキシ－ベンズイミダゾールｇｌｐ－１ｒ調節化合物 |
| CN117279905A (zh) * | 2021-04-21 | 2023-12-22 | 吉利德科学公司 | 羧基-苯并咪唑glp-1r调节化合物 |
| MX2023012918A (es) * | 2021-05-03 | 2024-03-13 | Carmot Therapeutics Inc | Agonistas del receptor del péptido 1 similar al glucagón (glp-1) de bencimidazoilo, composiciones farmacéuticas que los comprenden y métodos para su uso. |
| TWI843104B (zh) * | 2021-05-20 | 2024-05-21 | 美商美國禮來大藥廠 | 類升糖素肽1受體促效劑 |
| CN117355517A (zh) * | 2021-05-20 | 2024-01-05 | 伊莱利利公司 | 大环胰高血糖素样肽1受体激动剂 |
| AU2022300055A1 (en) * | 2021-06-24 | 2024-01-18 | Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. | Glp-1 receptor agonist and composition and use thereof |
| US20240382471A1 (en) * | 2021-07-21 | 2024-11-21 | Hepagene Therapeutics (HK) Limited | Glucagon-like peptide-1 receptor modulators and uses thereof |
| CN113480534B (zh) * | 2021-07-23 | 2022-05-13 | 广州必贝特医药股份有限公司 | 苯并咪唑或氮杂苯并咪唑-6-羧酸类化合物及其应用 |
| MX2024001331A (es) * | 2021-08-04 | 2024-04-19 | Shanghai Hansoh Biomedical Co Ltd | Regulador derivado del cicloalqueno, método de preparación de este y su aplicación. |
| AU2022335887A1 (en) | 2021-08-30 | 2024-04-18 | Mindrank Ai Ltd. | Novel aryl ether substituted heterocyclic compound as glp1r agonist |
| WO2023038039A1 (ja) | 2021-09-08 | 2023-03-16 | 塩野義製薬株式会社 | 抗肥満作用の関与する疾患の予防及び治療用医薬 |
| WO2023049518A1 (en) | 2021-09-27 | 2023-03-30 | Terns Pharmaceuticals, Inc. | Benzimidazole carboxylic acids as glp-1r agonists |
| WO2023057427A1 (en) | 2021-10-05 | 2023-04-13 | Astrazeneca Ab | Certain 2,5-diazabicyclo[4.2.0]octanes as glp-1 receptor modulators |
| WO2023057414A1 (en) | 2021-10-05 | 2023-04-13 | Astrazeneca Ab | Certain octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators |
| US20250115612A1 (en) | 2021-10-05 | 2025-04-10 | Astrazeneca Ab | Certain 2,5-diazabicyclo[4.2.0]octanes and octahydrofuro[3,4-b]pyrazines as glp-1 receptor modulators |
| TW202334129A (zh) | 2021-10-25 | 2023-09-01 | 美商拓臻製藥公司 | 作為ｇｌｐ—１ｒ促效劑的化合物 |
| JP2024543227A (ja) * | 2021-12-03 | 2024-11-19 | ハンチョウ サイウィンド バイオサイエンスィズ カンパニー リミテッド | チエノイミダゾール系化合物の結晶形及びその調製方法 |
| JPWO2023106310A1 (es) * | 2021-12-07 | 2023-06-15 | ||
| US20250042882A1 (en) | 2021-12-16 | 2025-02-06 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
| US20250066338A1 (en) | 2021-12-16 | 2025-02-27 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
| CN116354945B (zh) * | 2021-12-27 | 2024-08-30 | 长春金赛药业有限责任公司 | 一种稠合咪唑羧酸类化合物及其制备方法和应用 |
| WO2023130878A1 (zh) * | 2022-01-10 | 2023-07-13 | 海思科医药集团股份有限公司 | 一种glp-1激动剂盐及其晶型及在医药上的应用 |
| JP2025508812A (ja) | 2022-02-23 | 2025-04-10 | ターンズ・ファーマシューティカルズ・インコーポレイテッド | Ｇｌｐ－１ｒアゴニストとしての化合物 |
| EP4476208A1 (en) * | 2022-02-28 | 2024-12-18 | Ascletis Bioscience Co., Ltd. | Glp-1r modulating compounds |
| US20230271949A1 (en) * | 2022-02-28 | 2023-08-31 | Ascletis Bioscience Co., Ltd. | Glp-1r modulating compounds |
| EP4491625A1 (en) | 2022-03-08 | 2025-01-15 | Guangzhou Unirise Pharmaceutical Co., Ltd. | Benzo bicyclic compound, and preparation method and application thereof |
| CA3249144A1 (en) * | 2022-05-20 | 2025-06-17 | Chengdu Di'ao Jiuhong Pharmaceutical Factory | BENZIMIDAZOLE OR AZABENZIMIDAZOLE COMPOUND, ITS PREPARATION PROCESS AND ITS USE |
| CN119731181A (zh) * | 2022-06-23 | 2025-03-28 | 西藏海思科制药有限公司 | 一种噻吩[2,3-d]咪唑类化合物的盐及其晶型和在医药上的用途 |
| CN117362282A (zh) * | 2022-07-07 | 2024-01-09 | 杭州德睿智药科技有限公司 | Glp-1r激动剂的盐及其制备方法和应用 |
| WO2024041609A1 (zh) * | 2022-08-24 | 2024-02-29 | 广州市联瑞制药有限公司 | 苯并双环类化合物及其制备方法和应用 |
| WO2024051749A1 (zh) * | 2022-09-06 | 2024-03-14 | 德睿智药(苏州)新药研发有限公司 | 一种glp-1r激动剂化合物的多晶型物及其制备方法与用途 |
| EP4592285A1 (en) | 2022-09-22 | 2025-07-30 | Shionogi & Co., Ltd. | Fused ring compound having glp-1 receptor agonist effect |
| JP2025537254A (ja) | 2022-11-11 | 2025-11-14 | イーライ リリー アンド カンパニー | グルカゴン様ペプチド１受容体アゴニスト |
| JP2025538389A (ja) | 2022-11-16 | 2025-11-28 | イーライ リリー アンド カンパニー | グルカゴン様ペプチド１受容体アゴニスト |
| KR20250120402A (ko) * | 2022-12-13 | 2025-08-08 | 항저우 종메이화동 파마슈티칼 컴퍼니 리미티드 | Glp-1 수용체 작용제의 신규한 결정형, 이를 제조하기 위한 방법, 이의 약학 조성물 및 이의 용도 |
| CN116082321A (zh) * | 2022-12-23 | 2023-05-09 | 华中药业股份有限公司 | 一种咪唑并芳杂基类衍生物、药物组合物及其应用 |
| CN118496200A (zh) * | 2023-02-14 | 2024-08-16 | 成都康弘药业集团股份有限公司 | 吲唑啉酮类化合物及其制备方法和用途 |
| WO2024169952A1 (en) | 2023-02-16 | 2024-08-22 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| CN121335698A (zh) | 2023-04-07 | 2026-01-13 | 拓臻制药公司 | 用于治疗肝脏病症或心脏代谢疾病的包含THR-β激动剂和GLP-1R激动剂的组合 |
| WO2024212742A1 (zh) * | 2023-04-10 | 2024-10-17 | 上海研健新药研发有限公司 | 一种glp-1r激动剂，其制备方法和应用 |
| WO2025057134A2 (en) | 2023-09-14 | 2025-03-20 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
| WO2025109387A1 (en) | 2023-11-24 | 2025-05-30 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
| WO2025158275A1 (en) | 2024-01-24 | 2025-07-31 | Pfizer Inc. | Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds |
| KR20250125490A (ko) * | 2024-02-14 | 2025-08-22 | 주식회사 종근당 | Glp-1 수용체 작용제 및 이의 용도 |
| WO2025189141A1 (en) | 2024-03-08 | 2025-09-12 | Annapurna Bio, Inc. | Methods for treating obesity and increasing weight loss |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| AU2009221722B2 (en) * | 2008-03-07 | 2014-12-18 | Vtv Therapeutics Llc | Oxadiazoanthracene compounds for the treatment of diabetes |
| MX2012013130A (es) * | 2010-05-13 | 2013-04-11 | Amgen Inc | Compuestos heterociclicos de nitrogeno utiles como inhibidores de pde10. |
| AU2012352349B2 (en) | 2011-12-12 | 2017-08-17 | Receptos Llc | Carboxylic acid derivatives comprising four cycles acting as GLP-1 receptor modulators for therapy of diseases such as diabetes |
| EA037318B1 (ru) * | 2016-12-16 | 2021-03-11 | Пфайзер Инк. | Агонисты рецептора glp-1 и их применение |
| HUE061888T2 (hu) * | 2018-06-15 | 2023-08-28 | Pfizer | GLP-1 receptor agonisták és alkalmazásaik |
| UA130273C2 (uk) * | 2018-11-22 | 2026-01-07 | Цилу Реґор Терапьютикс Інк. | Агоністи glp-1r та їх застосування |
| PE20221040A1 (es) * | 2019-10-25 | 2022-06-17 | Gilead Sciences Inc | Compuestos moduladores de glp-1r |
| CN114761395B (zh) * | 2019-12-02 | 2024-11-15 | 现代药品株式会社 | Glp-1受体激动剂 |
| WO2021160127A1 (en) * | 2020-02-13 | 2021-08-19 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| TW202144340A (zh) * | 2020-04-03 | 2021-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用 |
-
2020
- 2020-04-10 PH PH1/2021/552557A patent/PH12021552557A1/en unknown
- 2020-04-10 CU CU2021000083A patent/CU20210083A7/es unknown
- 2020-04-10 CR CR20210562A patent/CR20210562A/es unknown
- 2020-04-10 MA MA055627A patent/MA55627A/fr unknown
- 2020-04-10 CA CA3136375A patent/CA3136375A1/en active Pending
- 2020-04-10 WO PCT/CN2020/084203 patent/WO2020207474A1/en not_active Ceased
- 2020-04-10 CN CN202080028229.XA patent/CN113853371B/zh active Active
- 2020-04-10 EP EP20788321.6A patent/EP3953344A4/en active Pending
- 2020-04-10 BR BR112021020335A patent/BR112021020335A2/pt unknown
- 2020-04-10 JP JP2021560022A patent/JP7635145B2/ja active Active
- 2020-04-10 MX MX2021012492A patent/MX2021012492A/es unknown
- 2020-04-10 PE PE2021001694A patent/PE20220143A1/es unknown
- 2020-04-10 EA EA202192684A patent/EA202192684A1/ru unknown
- 2020-04-10 AU AU2020256647A patent/AU2020256647B2/en active Active
- 2020-04-10 SG SG11202110825WA patent/SG11202110825WA/en unknown
-
2021
- 2021-10-08 CL CL2021002649A patent/CL2021002649A1/es unknown
- 2021-10-10 IL IL287128A patent/IL287128A/en unknown
- 2021-10-11 DO DO2021000208A patent/DOP2021000208A/es unknown
- 2021-10-11 SA SA521430550A patent/SA521430550B1/ar unknown
- 2021-11-08 CO CONC2021/0015060A patent/CO2021015060A2/es unknown
-
2023
- 2023-02-24 US US18/113,859 patent/US20230278991A1/en not_active Abandoned
-
2024
- 2024-09-10 US US18/830,194 patent/US20250042883A1/en active Pending
-
2025
- 2025-02-10 JP JP2025019723A patent/JP2025072577A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7635145B2 (ja) | 2025-02-25 |
| IL287128A (en) | 2021-12-01 |
| CU20210083A7 (es) | 2022-05-11 |
| JP2025072577A (ja) | 2025-05-09 |
| US20250042883A1 (en) | 2025-02-06 |
| AU2020256647A1 (en) | 2021-11-18 |
| PH12021552557A1 (en) | 2022-07-04 |
| BR112021020335A2 (pt) | 2021-12-14 |
| SA521430550B1 (ar) | 2025-04-14 |
| MA55627A (fr) | 2022-02-16 |
| AU2020256647B2 (en) | 2025-07-31 |
| CO2021015060A2 (es) | 2021-11-19 |
| JP2022527607A (ja) | 2022-06-02 |
| EA202192684A1 (ru) | 2021-12-28 |
| CN113853371B (zh) | 2024-05-03 |
| CA3136375A1 (en) | 2020-10-15 |
| SG11202110825WA (en) | 2021-10-28 |
| CL2021002649A1 (es) | 2022-05-06 |
| KR20210152513A (ko) | 2021-12-15 |
| CN113853371A (zh) | 2021-12-28 |
| EP3953344A4 (en) | 2023-08-09 |
| WO2020207474A1 (en) | 2020-10-15 |
| EP3953344A1 (en) | 2022-02-16 |
| DOP2021000208A (es) | 2021-11-21 |
| CR20210562A (es) | 2022-02-18 |
| US20230278991A1 (en) | 2023-09-07 |
| MX2021012492A (es) | 2021-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20220143A1 (es) | Agonistas de glp-1r y usos de los mismos | |
| PE20211871A1 (es) | Agonistas de glp-1r y usos de los mismos | |
| AR072952A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
| AR076551A1 (es) | Compuestos de 1-cianoetilheterociclilcarboxamida sustituida, composiciones farmaceuticas que los comprenden y su uso en el tratamiento de enfermedades mediadas por dppi | |
| AR052902A1 (es) | Derivados de piridazina, composicion farmaceutica que los contiene y su uso como agentes terapeuticos para enfermedades mediadas por la estearoil-coa desaturasa | |
| AR056548A1 (es) | Derivados de sulfonamidas, composiciones farmaceuticas y sus usos | |
| AR062937A1 (es) | Compuestos que modulan el receptor cb2 | |
| ES2929140T3 (es) | Imidazoles sustituidos con fenilo y piridinilo como moduladores de RORgammat | |
| AR064452A1 (es) | Derivados de 1,2,4 oxadiazol-indol,composiciones farmaceuticas que los comprenden y usos en trastornos asociados a receptores s1p1. | |
| CL2018000036A1 (es) | Derivados etinilo | |
| PE20210414A1 (es) | Compuestos inhibidores de rip1 y metodos para preparar y usar los mismos | |
| PE20171057A1 (es) | Derivados espirodiamina como inhibidores de la aldosterona sintasa | |
| PE20090218A1 (es) | Compuestos mimeticos de glucocorticoides, metodos de preparacion y composiciones farmaceuticas | |
| ECSP099324A (es) | Nuevos derivados de aminopirimidina como inhibidores de plk1 | |
| AR076219A1 (es) | Analogos de isoxazol-3 (2h)-ona como agentes terapeuticos | |
| PE20040164A1 (es) | Mimeticos de glucocorticoides, procedimientos para su preparacion y composiciones farmaceuticas | |
| PE20081475A1 (es) | Arilamidas sustituidas por tiazol u oxazol | |
| CO2020001326A2 (es) | Nuevos compuestos heterocíclicos como inhibidores de cdk8/19 | |
| AR078756A1 (es) | Moduladores alostericos positivos (map) | |
| AR053548A1 (es) | Derivados de oxiindol | |
| AR065280A1 (es) | Agentes antiparasitarios | |
| AR079260A1 (es) | Inhibidores de bencimidazol de la produccion de leucotrienos, un procedimiento para su preparacion, composiciones farmaceuticas que los comprenden y su empleo como medicamentos en el tratamiento de trastornos mediados por leucotrienos | |
| PE20081152A1 (es) | Azaciclilaminas n-sustituidas como antagonistas de histamina-3 | |
| AR056893A1 (es) | Compuestos heterociclicos fusionados y no fusionados, antagonistas de receptores mineralocorticoides | |
| BR112015005186A2 (pt) | 2-oxo-2,3-di-hidro-indóis para tratamento de distúrbios do snc |